A Pharmacokinetic Study of YN001 in Healthy Participants

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 27, 2025

Primary Completion Date

December 4, 2025

Study Completion Date

December 18, 2025

Conditions

Healthy Volunteers

Interventions

DRUG

YN001

YN001 administered via intravenous infusion. Participants will receive either 20 mg (Cohort 1) or 40 mg (Cohort 2).

Trial Locations (1)

CMAX Clinical Research, Adelaide

All Listed Sponsors

lead

Beijing Inno Medicine Co., Ltd.

INDUSTRY